Redesca
-
Steve Saviuk of Valeo Pharma talks about revenue growth following impressive market gains
In this InvestorIntel interview with host Tracy Weslosky, Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO…
-
Valeo Pharma revenues jump on increased market share from growing drug portfolio
Valeo Pharma Inc. (TSX: VPH | OTCQB: VPHIF) is a Canadian pharmaceutical company that is seeing significant success…
-
Steve Saviuk on Valeo Pharma’s TSX Listing and Q1-22 revenues of $4.2 million, up 128% over Q1-21
In a recent InvestorIntel interview, Tracy Weslosky interviews Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO…
-
Valeo Pharma’s rocketing growth in sales points to positive cash flow this year
Stock market investors love companies that can quickly expand and rapidly grow their revenues. The very best of…
-
Steve Saviuk of Valeo Pharma on record 2021 revenues, achieving breakeven in 2022, and uplisting on the TSX
In a recent InvestorIntel interview, Tracy Weslosky spoke with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH | OTCQB:…
-
Valeo Pharma is cashed up and ready to expand as COVID restrictions end
Are we starting to see the beginning of the end of COVID’s reign of terror over humanity? I…
-
Valeo Pharma’s Redesca™ rollout is progressing rapidly, proving the value of its business model, as its revenue grows 280% in Q3, 2021
Valeo Pharma Inc. (CSE: VPH | OTCQB: VPHIF | FSE: VP2) (“Valeo”) is a specialty pharmaceutical marketing company…
-
Valeo Pharma launches Redesca™ and is forecasting company revenues to increase 20x by 2025
Bringing new pharmaceutical products to market is a long and expensive process. One Canadian company has found an…
-
Valeo Pharma’s Steve Saviuk on Hesperidin and reducing the risk of securing COVID-19
In a new InvestorIntel interview Tracy Weslosky speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH…
-
Valeo Pharma on a significant upswing with recent Health Canada approvals
In a new InvestorIntel interview Peter Clausi speaks with Steve Saviuk, CEO of Valeo Pharma Inc. (CSE: VPH…
